Table 3.
Comparison of the severity indices at the day of tocilizumab administration of the propensity score matched cohort between the two arms to show the success of the matching
Tocilizumab | P value1 | ||||||
---|---|---|---|---|---|---|---|
No | Yes | ||||||
n | Mean | SD | n | Mean | SD | ||
On the day of admission | |||||||
Age (years) | 174 | 59.73 | 17.97 | 174 | 56.67 | 13.10 | 0.058 |
SpO2 | 162 | 91.24 | 7.10 | 171 | 90.79 | 6.96 | 0.053 |
Respiratory rate /min | 159 | 23.08 | 5.08 | 145 | 23.95 | 7.79 | 0.86 |
Lymphocytes at admission | 168 | 1.17 | 0.69 | 171 | 1.11 | 0.81 | 0.17 |
Neutrophils at admission | 166 | 5.39 | 4.95 | 170 | 4.97 | 3.73 | 0.62 |
WBC at admission | 168 | 7.21 | 5.15 | 158 | 6.13 | 4.02 | 0.048 |
On the day tocilizumab administration or similar days in the controls group | |||||||
Procalcitonin (µg/L) | 174 | 2.10 | 8.39 | 174 | 0.44 | 1.65 | 0.83 |
Neutrophils (103/mm3) | 171 | 6.87 | 6.89 | 174 | 5.49 | 3.23 | 0.99 |
Lymphocytes (103/mm3) | 171 | 0.93 | 0.61 | 174 | 0.98 | 0.90 | 0.63 |
d-dimer (mg/L) | 152 | 3.34 | 4.82 | 152 | 2.84 | 2.78 | 0.53 |
Ferritin (µg/L) | 174 | 819.46 | 605.32 | 174 | 1127.93 | 1294.91 | 0.11 |
CRP (mg/dl) | 173 | 4.43 | 5.71 | 173 | 4.19 | 4.63 | 0.23 |
1Wilcoxon–Mann–Whitney test